REG - Novacyt S.A. - DHSC Claim update – Pre-Trial Review

Novacyt SAAnnouncement

19/04/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240419:nRSS2453La&default-theme=true

RNS Number : 2453L  Novacyt S.A.  19 April 2024

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

 

DHSC Claim update - Pre-Trial Review

 

Paris, France, and Eastleigh and Manchester, UK - 19 April 2024 - Novacyt S.A.
(EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics
company with a broad portfolio of integrated technologies and services,
provides an update regarding its legal proceedings against the Department of
Health and Social Care ("DHSC").

 

As previously announced, the Company and its subsidiary Primer Design Ltd are
party to litigation with the DHSC. The trial hearing has been listed to
commence on 10 June 2024, and finish on 4 July 2024. The Company expects the
court to reserve judgment, meaning that the outcome of the trial will not be
known on 4 July 2024.

 

The court has listed the Pre-Trial Review to be heard on 30 April 2024. This
is part of the normal litigation process and is predominantly concerned with
administrative preparations for trial.

 

The court will also hear an application by the DHSC for summary judgment in
relation to one aspect of its claim, as part of which the DHSC is seeking
judgment to be entered for the full value of its claim. Having taken legal
advice, the Company considers this application to be very weak with low
prospects of success, and is confident that the court will dismiss the
application. It is not known when the court will give judgment in relation to
the application.  It may be during or at the end of the Pre-Trial Review, or
a short time thereafter.

 

The Company will announce the outcome of the application in due course.

 

Contacts

 

 Novacyt SA                                                              https://novacyt.com/investors (https://novacyt.com/investors/)
 James McCarthy, Acting Chief Executive Officer                           Via Walbrook PR
 Steve Gibson, Chief Financial Officer

 SP Angel Corporate Finance LLP (Nominated Adviser and Broker)                                             +44 (0)20 3470 0470
 Matthew Johnson / Charlie Bouverat (Corporate Finance)

 Vadim Alexandre / Rob Rees (Corporate Broking)

 Deutsche Numis (Joint Broker)                                                                             +44 (0)20 7260 1000
 Freddie Barnfield / Duncan Monteith / Michael Palser

 Allegra Finance (French Listing Sponsor)       +33 (1) 42 22 10 10

                                             r.durgetto@allegrafinance.com (mailto:r.durgetto@allegrafinance.com) /
 Rémi Durgetto / Yannick Petit                 y.petit@allegrafinance.com

 Walbrook PR (Financial PR & IR)                                         +44 (0)20 7933 8780 or novacyt@walbrookpr.com

 Stephanie Cuthbert / Paul McManus /                                     +44 (0)7796 794 663 / +44 (0)7980 541 893

 Phillip Marriage / Alice Woodings                                        +44 (0)7867 984 082 / +44 (0)7407 804 654

 

About Novacyt Group (www.novacyt.com (http://www.novacyt.com) )

Novacyt is an international molecular diagnostics company providing a broad
portfolio of integrated technologies and services, primarily focused on the
delivery of genomic medicine. The Company develops, manufactures, and
commercialises a range of molecular assays and instrumentation to deliver
workflows and services that enable seamless end-to-end solutions from sample
to result across multiple sectors including human health, animal health and
environmental.

 

The Company is divided into three business segments:

 

 Clinical           Broad portfolio of human clinical in vitro diagnostic products, workflows and
                    services focused on three therapeutic areas:

                    ·    Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy
                    tests

                    ·    Precision Medicine: DPYD genotyping assay

                    ·    Infectious Diseases: Winterplex, multiplex winter respiratory PCR
                    panel

 Instrumentation    Portfolio of next generation size selection DNA sample preparation platforms
                    and rapid PCR machines, including:

                    ·    Ranger® Technology: automated DNA sample preparation and target
                    enrichment technology

                    MyGo: real-time quantitative PCR (qPCR) instruments

 Research Use Only  Range of services for the research industry:

                    ·    Design, manufacture, and supply of high-performance qPCR assays and
                    workflows for use in human health, agriculture, veterinary and environmental,
                    to support global health organisations and the research industry

                    ·    Pharmaceutical research services: whole genome sequencing (WGS) /
                    whole exome sequencing (WES)

 

Novacyt is headquartered in Vélizy in France with offices in the UK (in
Stokesley, Eastleigh and Manchester), Taipei, Singapore, the US and Canada and
has a commercial presence in over 65 countries. The Company is listed on the
London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange
Euronext Growth ("ALNOV").

 

For more information, please refer to the website: www.novacyt.com
(http://www.novacyt.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDGPUQWCUPCPGR